- Home
- SONO vs NRIX Comparison
SONO vs NRIX Comparison
Compare SONO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- NRIX
- Stock Information
- Founded
- SONO 2002
- NRIX 2009
- Country
- SONO United States
- NRIX United States
- Employees
- SONO N/A
- NRIX N/A
- Industry
- SONO Consumer Electronics/Video Chains
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- NRIX Health Care
- Exchange
- SONO Nasdaq
- NRIX Nasdaq
- Market Cap
- SONO 1.1B
- NRIX 1.1B
- IPO Year
- SONO 2018
- NRIX 2020
- Fundamental
- Price
- SONO $10.04
- NRIX $12.78
- Analyst Decision
- SONO Buy
- NRIX Strong Buy
- Analyst Count
- SONO 3
- NRIX 17
- Target Price
- SONO $13.00
- NRIX $30.71
- AVG Volume (30 Days)
- SONO 1.7M
- NRIX 846.7K
- Earning Date
- SONO 05-07-2025
- NRIX 07-10-2025
- Dividend Yield
- SONO N/A
- NRIX N/A
- EPS Growth
- SONO N/A
- NRIX N/A
- EPS
- SONO N/A
- NRIX N/A
- Revenue
- SONO $1,463,138,000.00
- NRIX $56,417,000.00
- Revenue This Year
- SONO N/A
- NRIX $15.43
- Revenue Next Year
- SONO $3.27
- NRIX N/A
- P/E Ratio
- SONO N/A
- NRIX N/A
- Revenue Growth
- SONO N/A
- NRIX N/A
- 52 Week Low
- SONO $7.63
- NRIX $8.18
- 52 Week High
- SONO $16.30
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- SONO 48.87
- NRIX 70.71
- Support Level
- SONO $9.84
- NRIX $11.92
- Resistance Level
- SONO $10.38
- NRIX $12.59
- Average True Range (ATR)
- SONO 0.33
- NRIX 0.64
- MACD
- SONO -0.06
- NRIX 0.37
- Stochastic Oscillator
- SONO 35.78
- NRIX 92.17
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.